Genomic Health Inc. (GHDX) Insider Sells $89,040.00 in Stock
Genomic Health Inc. (NASDAQ:GHDX) insider James J. Vaughn sold 3,000 shares of the stock in a transaction dated Thursday, October 6th. The stock was sold at an average price of $29.68, for a total transaction of $89,040.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
James J. Vaughn also recently made the following trade(s):
- On Monday, August 8th, James J. Vaughn sold 3,000 shares of Genomic Health stock. The shares were sold at an average price of $28.74, for a total transaction of $86,220.00.
Genomic Health Inc. (NASDAQ:GHDX) opened at 30.48 on Wednesday. Genomic Health Inc. has a 12-month low of $20.05 and a 12-month high of $35.79. The company’s market cap is $1.02 billion. The firm’s 50-day moving average is $28.15 and its 200 day moving average is $27.27.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/genomic-health-inc-ghdx-insider-sells-89040-00-in-stock.html
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The company earned $81.97 million during the quarter, compared to analyst estimates of $81.27 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. Genomic Health’s revenue was up 16.1% on a year-over-year basis. On average, equities analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of GHDX. Schwab Charles Investment Management Inc. raised its position in shares of Genomic Health by 63.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 127,652 shares of the company’s stock valued at $3,306,000 after buying an additional 49,512 shares during the last quarter. American Century Companies Inc. acquired a new position in shares of Genomic Health during the second quarter valued at approximately $735,000. AQR Capital Management LLC acquired a new position in shares of Genomic Health during the second quarter valued at approximately $270,000. Motley Fool Wealth Management LLC raised its position in shares of Genomic Health by 5.7% in the second quarter. Motley Fool Wealth Management LLC now owns 123,018 shares of the company’s stock valued at $3,186,000 after buying an additional 6,622 shares during the last quarter. Finally, Allianz Asset Management AG raised its position in shares of Genomic Health by 70.6% in the second quarter. Allianz Asset Management AG now owns 24,560 shares of the company’s stock valued at $636,000 after buying an additional 10,160 shares during the last quarter. 88.92% of the stock is owned by institutional investors.
A number of research firms have recently weighed in on GHDX. Canaccord Genuity restated a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Tuesday, October 4th. Bank of America Corp. set a $28.00 price target on shares of Genomic Health and gave the company a “sell” rating in a research note on Wednesday, August 3rd. Jefferies Group raised their price target on shares of Genomic Health from $25.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, August 17th. Finally, Leerink Swann restated a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $32.50.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.